

NOVO NORDISK A S  
Form 6-K  
February 15, 2011

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**FORM 6-K**

---

**REPORT OF FOREIGN PRIVATE ISSUER**

Pursuant to Rule 13a-16 or 15d-16  
of the Securities Exchange Act of 1934

**February 15, 2011**

---

**NOVO NORDISK A/S**

(Exact name of Registrant as specified in its charter)

**Novo Allé  
DK- 2880, Bagsvaerd  
Denmark**

(Address of principal executive offices)

---

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F  Form 40-F

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  No

If  Yes is marked, indicate below the file number assigned to the registrant in connection with Rule 12g-32(b):82-\_\_\_\_\_



## Company Announcement

14 February 2011

## Novo Nordisk A/S – Share repurchase programme

On 2 February 2011 Novo Nordisk initiated a share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.

Under the programme Novo Nordisk will repurchase B shares for an amount up to DKK 2.0 billion in the period from 2 February 2011 to 26 April 2011.

Since the announcement as of 7 February 2011, the following transactions have been made under the programme:

	<b>Number of shares</b>	<b>Average purchase price</b>	<b>Transaction value, DKK</b>
<b>Accumulated, last announcement</b>	187,000		113,718,833
07 February 2011	60,000	612.6500	36,759,000
08 February 2011	60,000	614.6400	36,878,400
09 February 2011	55,000	628.6900	34,577,950
10 February 2011	60,000	641.1000	38,466,000
11 February 2011	60,000	649.7000	38,982,000
<b>Accumulated under the programme</b>	<b>482,000</b>		<b>299,382,183</b>

Transactions related to Novo Nordisk's incentive programmes have resulted in a net sale by Novo Nordisk of 289,631 B shares in the period from 7 February 2011 to 11 February 2011. The shares in these transactions were not part of the Safe Harbour repurchase programme.

<b>Novo Nordisk A/S</b>	Novo Allé	Telephone:	Internet:	CVR no:
Investor Relations	2880 Bagsværd	+45 4444 8888	novonordisk.com	24256790
	Denmark	Telefax:		
		+45 4444 6626		

---

With the transactions stated above, Novo Nordisk owns a total of 27,786,437 treasury shares, corresponding to 4.6% of the share capital. The total amount of shares in the company is 600,000,000 including treasury shares.

Novo Nordisk expects to repurchase B shares worth DKK 10.0 billion during 2011. As of 11 February 2011, Novo Nordisk has repurchased a total of 482,000 B shares equal to a transaction value of DKK 299,382,183.

*Novo Nordisk is a global healthcare company with 87 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately 30,900 employees in 76 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit [novonordisk.com](http://novonordisk.com).*

For further information please contact:

Media:

Anne Margrethe Hauge

Tel: (+45) 4442 3450

[amhg@novonordisk.com](mailto:amhg@novonordisk.com)

Investors:

Klaus Bülow Davidsen

Tel: (+45) 4442 3176

[klda@novonordisk.com](mailto:klda@novonordisk.com)

Kasper Roseeuw Poulsen

Tel: (+45) 4442 4471

[krop@novonordisk.com](mailto:krop@novonordisk.com)

Jannick Lindegaard

Tel: (+45) 4442 4765

[jlis@novonordisk.com](mailto:jlis@novonordisk.com)

*In North America:*

Ken Inchausti

Tel: (+1) 609 514 8316

[kiau@novonordisk.com](mailto:kiau@novonordisk.com)

*In North America:*

Hans Rommer

Tel: (+1) 609 919 7937

[hrrm@novonordisk.com](mailto:hrrm@novonordisk.com)

Company Announcement no 8 / 2011

Page 2 of 2

<b>Novo Nordisk A/S</b>	Novo Allé	Telephone:	Internet:	CVR no:
Investor Relations	2880 Bagsværd	+45 4444 8888	novonordisk.com	24256790
	Denmark	Telefax:		
		+45 4444 6626		

---

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.

Date: February 15, 2011

NOVO NORDISK A/S

Lars Rebien Sørensen,

President and Chief Executive Officer

---



